GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	117.55B
Revenue (ttm)	61.15B
Net Income (ttm)	8.10B
Shares Out	318.47M
EPS (ttm)	25.43
PE Ratio	14.52
Forward PE	n/a
Dividend	10.00 (2.71%)
Ex-Dividend Date	Apr 18, 2025

Volume	588,318
Average Volume	796,433
Open	378.00
Previous Close	375.63
Day's Range	366.00 - 378.00
52-Week Range	118.00 - 481.00
Beta	0.34
RSI	44.52
Earnings Date	Apr 28, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.